Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Antony Mattessich – CEO Donald Notman – CFO Dr. Michael Goldstein – Chief Medical Officer Scott Corning – Senior Vice President Commercial Chris White – Chief Business Officer Conference Call Participants Jon Wolleben – Participants Dane Leone – Raymond James Joe Catanzaro – Piper Sandler David Steinberg – Jefferies Anita Dushyanth – Berenberg Capital Georgi Yordanov – Cowen and Company Y ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) Delaware 20-5560161 24 Crosby Drive Bedford, MA 01730 (Address of principal executive offices) (Zip ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2021 Results Conference Call August 9, 2021 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Dr. Michael Goldstein - President-Ophthalmology and Chief Medical Officer Scott Corning - Senior Vice President, Commercial Chris White - Senior Vice President, Business and Corporate Development Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Georgi Yord ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 (Address of principal executive offices) (Zip Code) (781) 357-4000 (Registrant's telephone number, inclu ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President and Chief Executive Officer Michael Goldstein – President-Ophthalmology and Chief Medical Officer Conference Call Participants Joe Catanzaro – Piper Sandler Jonathan Wollenben – JMP Securities Georgi Yordanov – Cowen and Company Ed Chung – Jefferies Anita Dushyanth – Berenberg Boobalan Pachaiyappan – H.C. Wainwright Operator ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (St ...

(NASDAQ: OCUL) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER March 2021 FORWARD LOOKING STATEMENTS Any statements in this presentation about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates; the commercial launch of, and effectiveness of reimbursement codes for, DEXTENZA; the conduct of post-approval studies of DEXTENZA; the develo ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Antony Mattessich - Chief Executive Officer Michael Goldstein - Chief Medical Officer Patricia Kitchen - Chief Operating Officer Donald Notman - Chief Financial Officer Conference Call Participants Dane Leone - RJF David Steinberg - Jefferies Joe Catanzaro - Piper Sandler Jon Wolleben - JMP Securities Georgi Yordanov - Cowen & Company Anita Dushyanth - Berenberg Capital Market Yi Chen - H.C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or ...